179 related articles for article (PubMed ID: 25042151)
1. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G
Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
Koonce NA; Griffin RJ; Dings RPM
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232825
[TBL] [Abstract][Full Text] [Related]
4. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
Gheysen L; Soumoy L; Trelcat A; Verset L; Journe F; Saussez S
Cells; 2021 May; 10(5):. PubMed ID: 34063063
[TBL] [Abstract][Full Text] [Related]
5. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
6. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
Leung Z; Ko FCF; Tey SK; Kwong EML; Mao X; Liu BHM; Ma APY; Fung YME; Che CM; Wong DKH; Lai CL; Ng IO; Yam JWP
J Exp Clin Cancer Res; 2019 Oct; 38(1):423. PubMed ID: 31640796
[TBL] [Abstract][Full Text] [Related]
7. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment.
Michael JV; Wurtzel JG; Goldfinger LE
Anticancer Res; 2016 Oct; 36(10):5053-5061. PubMed ID: 27798864
[TBL] [Abstract][Full Text] [Related]
9. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
10. Effects of galectin-1 inhibitor OTX008 on oral squamous cell carcinoma cells in vitro and the role of AP-1 and the MAPK/ERK pathway.
Greer PFC; Rich A; Coates DE
Arch Oral Biol; 2022 Feb; 134():105335. PubMed ID: 34891102
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
12. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
13. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
14. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling.
Chen YJ; Cheng YJ; Hung AC; Wu YC; Hou MF; Tyan YC; Yuan SS
Gynecol Oncol; 2013 Dec; 131(3):734-43. PubMed ID: 24145114
[TBL] [Abstract][Full Text] [Related]
15. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
[TBL] [Abstract][Full Text] [Related]
16. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
17. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
19. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
Hu J; Cheng Y; Li Y; Jin Z; Pan Y; Liu G; Fu S; Zhang Y; Feng K; Feng Y
Eur J Cancer; 2014 Sep; 50(13):2336-50. PubMed ID: 25001183
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.
Foster PA; Stengel C; Ali T; Leese MP; Potter BV; Reed MJ; Purohit A; Newman SP
Anticancer Res; 2008; 28(3A):1483-91. PubMed ID: 18630502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
